A Study of AK104 Plus Axitinib in Advanced/Metastatic Special Pathological Subtypes of Renal Cell Carcinoma

NCT05808608 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

37

Enrollment

OTHER

Sponsor class

Conditions

Renal Cell Carcinoma
First-line Treatment
Non Clear Cell Renal Cell Carcinoma
Sarcomatoid Renal Cell Carcinoma

Interventions

DRUG: AK104
DRUG: Axitinib

Sponsor

Hao Zeng